BC
RGNX icon

Bridgefront Capital’s Regenxbio RGNX Stock Holding History

Bridgefront Capital’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,042
Closed -$159K – 727
2025
Q4 		$159K Buy
+11,042
New +$138K 0.04% 478
2021
Q2 		– Sell
-10,237
Closed -$349K – 855
2021
Q1 		$349K Buy
+10,237
New +$437K 0.11% 369

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bridgefront Capital's RGNX Position: Q1 2026 in Review

Bridgefront Capital sold out of Regenxbio (RGNX) in Q1 2026, closing a stake of 11,042 shares — an estimated $159K sold.

Bridgefront Capital first reported a position in RGNX in Q1 2021 and held it in 2 quarters. The position peaked at $349K in Q1 2021. 178 funds tracked by Wall St. Rank hold RGNX as of Q1 2026.

  • Bridgefront Capital reported no remaining Regenxbio position as of Q1 2026 after selling out during the quarter.
  • Bridgefront Capital sold 11,042 Regenxbio shares in Q1 2026, an estimated $159K.
  • Bridgefront Capital first reported a position in Regenxbio in Q1 2021 and held it in 2 quarters.
  • Bridgefront Capital's Regenxbio position peaked at $349K in Q1 2021.
  • 178 funds tracked by Wall St. Rank held Regenxbio as of Q1 2026.

Based on Bridgefront Capital's 13F filing for Q1 2026, filed 15 May 2026.